Epstein Secrets

ons taken at committee meetings. The Supervisory Board therefore always had extensive and well-founded information on all matters of significance in the Evonik Group. At its meeting in March, the Supervisory Board focused on examining the annual financial state- ments, which had first been considered in detail by

s: • Executive Committee: Dr. Werner Muller (Chairman), Michael Vassiliadis (Deputy Chairman), ainter Adam (until December 10, 2015), Ralf Hermann, Steven Koltes and Dr. Volker Trautz. • Audit Committee: Dr. Siegfried Luther (Chairman and independent financial expert within the meaning of Section 100 Paragra

ting, for example, from legal disputes such as claims for compensation, and from administrative proceedings and fines. In its operating busi- ness, the Evonik Group is exposed to liability risks, especially in connection with product liability, patent law, tax law, com- petition law, antitrust law and environmen

30 30 9 9 129 129 Ralf Hermann 90 90 58 58 10 9 158 157 Prof. Wolfgang A. Herrmann 90 90 5 95 95 Dieter Kleren 90 90 95 95 Steven Koltes 90 90 45 45 8 S 143 140 Frank Ldllgen (from May 1, 2014) 90 60 28 18 8 7 126 85 Dr. Siegfried Luther 90 90 45 45 10 10 145

PPLEMENTARY INFORMATION Independent Auditor's Report Report on the Group Management Report We have audited the accompanying management report for the Evonik Group, which is combined with the management report of the company, Evonik Industries AG, Essen, for the business year from January 1 to December 31, 201

OUR SHAREHOLDERS MANAGEMENT REPORT CONSOLIDATED CINANCIN. STATEMENTS • SUPPLEMENTARY INFORMATION 215 Further Information on corporate officers Steven Koltes, St. Moritz (Switzerland) Co-Chairman CVC Capital Partners Group b) Frontiers Media S.A. (Switzerland) Kaltroco Limited (Jersey) Frank Lollgen, C